Review Article

Do Probiotics Improve the Health Status of Individuals with Diabetes Mellitus? A Review on Outcomes of Clinical Trials

Periyanaia Kesika *, Bhagavathi Sundaram Sivamaruthi **, and Chaiyavat Chaiyasut ***

Innovation Center for Holistic Health, Nutraceuticals, and Cosmeceuticals, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand

Correspondence should be addressed to Chaiyavat Chaiyasut; chaiyavat@gmail.com

Received 3 June 2019; Revised 22 July 2019; Accepted 19 August 2019

Academic Editor: Swaran J. S. Flora

Copyright © 2019 Periyanaia Kesika et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Probiotics are now considered as an adjuvant and complementary therapeutic agent for several health complications, especially for metabolic and gastrointestinal disorders because of the influential impact of probiotic consumption on gut microbiota and immunity. Diabetes mellitus (DM) is fourth, in noncommunicable disease category, leading cause of mortality, morbidity, and economic crises in the world. Though several progressions are added in the medical field in recent decades, the treatment and management of diabetic-related health issues are still challenging. The present study summarizes the effects of probiotic supplementation on the health status of diabetic patients. The relevant information was collected from Scopus, PubMed, and Google Scholar. The detailed literature survey revealed that the consumption of probiotic supplementation significantly improved the overall health condition of diabetic patients. Especially, the probiotic intervention improved the fasting blood glucose, insulin sensitivity, and systemic inflammatory and antioxidant status in type 2 diabetic (T2D) patients. Moreover, improvement of gut microbial composition and prevention of bacterial translocation has also been observed in probiotic-supplemented T2D people. Some of the studies evidenced that the supplementation of probiotics can prevent and improve the gestational DM. Nevertheless, some of the studies reported negative results and limitations in the results of clinical trials. However, further studies are mandatory to develop a concrete probiotic-based adjuvant treatment procedure to treat DM.

1. Introduction

Diabetes mellitus (DM) is one of the major threats to human health and considered as the fourth most common noncommunicable diseases (NCD). A recent report in Lancet Global Health [1] revealed that diabetes-associated health loss increased drastically in India since 1990, which is highest among the NCD. The incidence of DM in the US also increasing at an uncontrolled rate, and the number of Americans with DM might increase up to 55 million by 2030 [2]. The global costs of management of diabetes and its consequences are increasing and predicted that it may reach up to US$2.1 trillion in 2030 [3].

Type 2 DM (T2D) accounts for 90–95% of DM incidences and is characterized by high blood glucose level, insulin deficiency and resistance [4]. Untreated DM is associated with the development of health difficulties that may compromise the quality of life and may increase the risk of mortality. T2D also affects the psychological and social life of most of the patients, and T2D patients are often found with some psychological problems like stress, depression, and anxiety [5].

Apart from heredity, dietary behavior, lack of physical activities, obesity, and some medication are the major factors associated with the incidence of DM. Recent studies evidenced that host microbiome play a critical role in the incidence and management of DM, especially in T2D [6]. The inconsistency of gut microbiota (GM), termed as dysbiosis, is greatly associated with T2D, and it has been reported that GM of T2D patient comprised of opportunistic pathogens and reduced number of beneficial microbes, especially butyrate-producing bacteria [7]. The improvement of gut health may aid to manage the diabetic conditions that may prevent the development of further DM-associated health complications.

Probiotics are live microbes that, when consumed in sufficient amounts, confer a health benefit to the humans [8]. Probiotics have been recognized for their several
health-promoting properties, and ameliorating the physiological and psychological hitches and distress [9–13]. Though several studies reported that Lactobacillus species confer positive impact on host health, the beneficial effects of probiotics are strain-specific, and also related to the host physiology. Recently, Akkermansia muciniphila has been considered as a potential bacteria that could be used to treat T2D, and A. muciniphila improves the glucose intolerance in diabetic mice [14], but the use of A. muciniphila in human need further advancement in the preparation of the therapeutic agent and detailed validation.

In recent decades, several clinical trials have been conducted to evaluate the antidiabetic nature of probiotic preparations. All the studies have their merits and demerits, and the results are inconclusive. Numerous meta-analysis reports also emphasized the key findings of the clinical trials and specified some points that need to be considered in clinical trials. The current manuscript was prepared with the aim of summarizing the significant findings of antidiabetic properties of probiotics concerning the outcomes of studies conducted in human volunteers. The antidiabetic activity of the probiotics on the mechanism of T2D conditions are illustrated in Figure 1.

2. Antidiabetic Properties of Probiotic Supplements

2.1. Probiotic Supplement. The supplementation of a mixture of probiotics strains such as Bifidobacterium bifidum W23, B. lactis W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, L. lactis W19, and Lactococcus lactis W58 (Ecologic®Barrier) at the final concentration of 2.5 billion cells per gram (two gram per day) for 26 weeks were expected to significantly reduce the systemic inflammatory status, inflammatory responses, endotoxins level in T2D patients [15]. Though Alokail et al. [15] already reported a study protocol to investigate the beneficial impact of Ecologic®Barrier in T2D patients, a recent study showed that the short term (12 weeks) supplementation of Ecologic®Barrier improved the HOMA-IR value and some anthropometric parameters (waist-hip ratio), but [15] no changes were observed in the endotoxin level in T2D patients [16], [16]. Sabico et al. [17] extended the study following the protocol [15] with extended duration (6 months) to evaluate the potential of Ecologic®Barrier. The results revealed that the supplementation of Ecologic®Barrier significantly reduced the circulating endotoxin level, fasting plasma glucose (FPG), TG (triglycerides), HOMA-IR (Homeostasis model of assessment-insulin resistance), insulin, total cholesterol (TC), TC: HDL (high-density lipoprotein) ratio, inflammatory markers (TNF-α, IL-6), C-reactive protein (CRP), resistin in T2D patients. Moreover, the increase in adiponectin concentration was observed after probiotic supplementation. The results revealed that the supplementation of probiotics may improve the health status of T2D patients if the intervention lost for an optimum duration [17].

The intervention of probiotic preparation consists of a various concentration of L. acidophilus, L. casei, L. rhamnosus, L. bulgaricus, B. breve, B. longum, and Streptococcus thermophilus strains along with fructo-oligosaccharide (FOS) for 8 weeks significantly reduced the fasting plasma glucose (FPG) level in T2D patients compared to that of the placebo control. The level of both serum insulin and LDL (low-density lipoprotein) was increased in the probiotic and placebo group. HOMA-IR score was increased compared to baseline but HOMA-IR score in probiotic group was relatively low compared to that of the placebo control. Moreover, probiotic supplementation significantly improved the level of glutathione in T2D patients, which suggested that probiotic supplementation improved the antioxidant status of the patient and control the diabetic condition by reducing the glucose level [18]. Likely, the supplementation of multispecies probiotic preparation along with 100 mg FOS significantly increased the serum calcium level and decreased the ALT (alanine aminotransferase) in T2D patients, while no influence on other serum minerals such as zinc, iron, magnesium, and liver enzymes such as alkaline phosphatase and aspartate aminotransferase were observed [19]. Recently, a study reported that the same multistrain probiotic intervention along with 100 mg FOS improved the glycemic status of T2D patients. Even though the notable amount of reduction was observed in FPG and increase in HDL, there were no changes in insulin resistance, TG, TC and insulin levels, and anthropometric values like BMI (body mass index), chest, hip, and waist circumferences. Yet supplementation of multistrain probiotic preparation with FOS improved the FPG status in T2D patients, further studies are needed to confirm the beneficial effect of the probiotic interventions [20].

The supplementation of synbiotic preparation (1 × 10⁷ CFU of L. sporgenes, 40 mg inulin, 380 mg isomalt, and 360 mg sorbitol, and 50 mg stevia per gram; 9 g of synbiotic thrice a day) for six weeks significantly improved the metabolic status of T2D patients. Specifically, the synbiotic group showed a notable level of decrease in serum insulin, hs-CRP levels, and increased glutathione and uric acid level compared to control. There were no significant changes noticed in TC value, HOMA-IR score, and LDL level. Also, the total antioxidant capacity of the system was not affected by the synbiotic intervention. The results showed that synbiotic supplementation can improve the metabolic status of T2D patients [21].

The intervention of multistrain probiotic mixture (10¹⁰ CFU per day; L. acidophilus, L. casei, L. lactis, B. bifidum, B. longum, and B. infantis) for 12 weeks showed no significant improvement in HOMA-IR, QUICKI (Quantitative insulin sensitivity check index), hs-CRP, and lipid profile except modest improvement of fasting insulin and HbA1c levels [22].

The consumption of L. reuteri ADR-1 and L. reuteri ADR-3 improved the fecal microbial composition and DM-associated complications in T2D patients. The consumption of live cells of probiotic confers better health benefits compared to that of the heat-killed cells. The level of HbA1c, TC and blood pressure was found to be decreased significantly. The fecal Lactobacillus and Bifidobacterium load were also increased after the probiotic intervention, which was positively correlated with the amount of L. reuteri in the fecal sample. The antioxidant and inflammatory status of the patients were not affected by the probiotic supplementation. Both the strains of L. reuteri exhibited health-promoting property with unique
influences on fecal microbiota and other DM-associated parameters [23].

T2D patients were supplemented with two different doses (10^9 or 10^10 CFU per day) of a single strain of *L. reuteri* DSM 17938 for 12 weeks and changes in the selected biomarkers were assessed. The results showed that DSM 17938 consumption did not improve the HbA1c, and biomarkers related to adiposity, liver steatosis, and fecal microbial composition, whereas, consumption of a high dose of DSM 17938 improved the insulin sensitivity index and serum deoxycholic acid, which was correlated with each other and microbiotal composition. The study claimed that further studies are required to confirm the findings with respect to individual variations [24].
The supplementation of symbiter (a combination of different concentrations of 14 probiotic strains of *Bifidobacterium*, *Lactobacillus*, *Lactococcus* and *Propionibacterium* species, and *Acetobacter* genera) for eight weeks improved the insulin resistance in T2D patients. Specifically, the HOMA-IR score and HbA1c value were found to be reduced significantly in the probiotic-supplemented group, especially among the probiotic responders, compared to that of the placebo, but no significant changes were observed in inflammatory markers such as IL-6, IL-8, and INF-γ except TNF-α and IL-1β [25].

T2D patients were either supplemented with symbiotic formula (500 mg/day; containing *Lactobacillus*, *Bifidobacterium* species, *S. thermophilus*, and FOS) or placebo formula for nine weeks. The influence of symbiotic supplementation on DM-associated parameters has been assessed. The results showed that the test intervention significantly reduced the FPG, HbA1c, and BMI values compared to that of the control group, whereas, there was no significant improvement in lipid, TC, urea, and creatinine profile in both groups at the end of the study. The study concluded that the supplementation of a specific amount of specified symbiotic formulation merely improved the FPG, HbA1c, and BMI value in T2D patients [26].

The consumption of symbiotic shake containing *L. acidophilus*, *B. bifidum*, and FOS for thirty days significantly improved the glycemic status and reduced the TC and TG levels in T2D patients. A notable level of improvement in HDL content was also observed in symbiotic shake supplemented group compared to that of the placebo [27].

The supplementation of symbiotic supplements (2 × 10^9 CFU of each *L. acidophilus*, *L. casei* and *B. bifidum*, and 800 mg insulin per day) for 12 weeks significantly reduced the FPG, insulin, and HOMA-β cell function score, and increased the insulin sensitivity index and HDL content in obese T2D patients with coronary heart disease compared to that of the placebo control and baseline values [28].

The supplementation of the probiotic mixture (*L. salivarius* UBLS 22, *L. casei* UBLC42, *L. plantarum* UBLP40, *L. acidophilus* UBLA34, *B. breve* UBBR01, *Bacillus coagulans* Unike-I52) and prebiotic (FOS) for 12 weeks improved the glycemic control and health status of T2D patients compared to that of the placebo control. Based on the intragroup analysis, the study stated that the health benefits of symbiotic supplementation correlated with the age of the patients while not associated with gender variation [29].

Gestational DM (GDM) is one of the metabolic complications of pregnancy to the susceptible individuals with the incidence of 3–25%, and probiotic supplementation may ameliorate glycemic control in GDM patients [30]. The supplementation of the probiotic capsule that consists of four probiotic strains (*L. acidophilus* LA-5, *L. delbrueckii bulgaricus* LBY-27, *S. thermophilus* STY-31, and *Bifidobacterium* BB-12; 4 × 10^9 CFU in total) for eight weeks hindered the weight gaining process after 6 weeks of the intervention compared to the placebo group in recently diagnosed GDM patients. The level of FPG was reduced in all the subjects, but significant reduction was observed in the probiotic-supplemented group. Insulin resistance index and Insulin sensitive index (ISI) were reduced and increased in the probiotic group, respectively, but the ISI value was not significantly different from that in the placebo group [31]. Similarly, the antioxidant status and inflammatory profile of the GDM patients were found to be improved after the probiotic (*L. bulgaricus* LBY-27, *L. acidophilus* LA-5, *S. thermophilus* STY-31, *Bifidobacterium* BB-12) intervention [32]. The results suggested that probiotic intervention has a beneficial impact on GDM patients and a further detailed study is needed to claim the therapeutic credit to the studied probiotic preparation.

About eight weeks of supplementation of VSL#3 (a mixture of *L. acidophilus*, *L. plantarum*, *L. paracasei*, *L. delbrueckii subsp. Bulgaricus*, *B. breve*, *B. longum*, *B. infantis*, and *S. thermophilus*; 1.125 × 10^11 CFU per capsule) failed to improve the FPG and HbA1c values in GDM patients, whereas, a significant level of reduction was observed in IL-6, hs-CRP, TNF-α concentration after probiotic supplementation. HOMA-IR value and insulin levels were also different among the probiotic and control groups while no notable changes were observed in IL-10. Further studies are required to conclude the beneficial effect of VSL#3 on the health status of GDM patients [33]. Interestingly, supplementation of the probiotic mixture (*L. acidophilus*, *L. casei*, and *B. bifidum*; 2 × 10^9 CFU each) significantly amended the health status of GDM patient. A significant reduction of FPG, TG, VLDL (very low density lipoprotein), insulin level, HOMA-IR, and HOMA-β-cell function were observed in the probiotic supplemented group compared to that of the placebo control after 6 weeks. The insulin sensitivity of the patient was also increased at a notable level, while the lipid profile was not improved during the study period. The study claimed that the supplementation of prescribed probiotic formula at a specified concentration may improve the overall health status of GDM patient [34]. A four-week supplementation of Infoloran® (10^9 cells each; *L. acidophilus*, and *B. bifidum*) to GDM patients improved the metabolic status of the subjects. A notable level of improvement was observed in FPG, fasting insulin level, and HOMA-IR score in the probiotic-supplemented group compared to that of the placebo control. There was no change in weight gain between the groups. The results disclosed that the supplementation of probiotic could improve glycemic control in GDM patients [35]. The supplementation of probiotic strain *L. rhamnosus* HN001 to pregnant women, starting from 14 to 16 weeks of gestation, reduced the risk of development of GDM, especially in older women with the previous history of GDM [36].

DM preventing properties of probiotic supplementation has also been studied in pre-diabetic people. Effect of supplementation of probiotic or symbiotic preparation on glycemic control of pre-diabetic people has been studied in a double-blind, randomized controlled clinical trial. The subjects were randomly divided and supplemented with probiotic (each 10^6 CFU; *L. acidophilus*, *B. lactis*, *B. bifidum*, and *B. longum*) or symbiotic (probiotic + inulin) or placebo for 24 weeks. The analyses of selected parameters showed that the supplementation of symbiotic preparation significantly reduced the FPG, HbA1c, fasting insulin level, and HOMA-IR score, and also increased the QUICKI score compared to that of the placebo control and probiotic group. HOMA-β-cell function score was found to be not affected by any of the intervention.
The results of the study suggested that the intervention of synbiotic preparation may reduce the risk of developing the metabolic disorder in prediabetic people, but detailed studies are needed [37]. In another study, Kassaian et al. [38] studied the beneficial effect of probiotic and synbiotic formulation, slightly increased concentration (each 1.5 × 10^7 CFU), in prediabetic people. The results showed that the supplementation of probiotic and synbiotic may reduce the risk of metabolic syndrome, and also aids to manage the metabolic disorders [38] (Table 1).

2.2. Probiotic Soymilk. The supplementation of probiotic soymilk improved the kidney function in T2D patients. Eight-week randomized-controlled study with T2D patients showed the beneficial impact of consumption of soymilk containing L. plantarum A7 (200 ml per day) in terms of improvement of kidney function. The studied parameters such as urine albumin level, serum creatinine, sialic acid, and IL-18 levels were reduced in the probiotic-supplemented group compared to that of the control, and a significant level of improvement in estimated glomerular filtration rate was also observed in the treatment group. The results suggested that the supplementation of L. plantarum A7 containing soymilk improved the kidney function [39]. Similarly, the supplementation of probiotic soymilk improved some of the oxidative stress markers in patients with diabetic kidney disease (DKD). Specifically, about eight-week consumption of probiotic soymilk increased the level of reduced glutathione, glutathione peroxidase, and glutathione reductase in DKD patients, while no changes were observed in MDA (malondialdehyde) and 8-iso-prostaglandin F2α values, and total antioxidant capacity [40].

2.3. Fermented Milk Containing Probiotic. The consumption of 300 g of probiotic yogurt (PY; comprising of L. acidophilus La5 and B. lactis Bb12) for six weeks significantly improved the lipid profile in T2D patients. The level of TC and LDL was reduced in PY supplemented group compared to baseline and to that of the conventional yogurt group (control). Though no significant changes were observed in TG and HDL, the ratio of TC: HDL, and LDL: HDL was reduced in the probiotic group [41]. In another arm, the consumption of PY improved the antioxidant status of T2D patients. The level of SOD (superoxide dismutase), GPx (glutathione peroxidase), and TAS (total antioxidant status) was increased in PY group compared to that of the control and baseline value. The level of MDA was reduced after PY consumption, while no significant changes were observed in insulin and CAT (catalase) levels [42]. Overall, results suggested that the consumption of probiotic yogurt may reduce the risk of cardiovascular diseases and improved the radical scavenging system in T2D patients [41, 42]. Another study by Rezaei et al. [43] showed that consumption of 300 g of PY per day for four weeks significantly improved the glycemic status (reduced the FPG, and HbA1c), and serum lipid concentration (reduced the LDL) compared to baseline values. [43]. Drinking fermented milk containing L. casei strain Shirota (FMLCS) for 16 weeks significantly altered the fecal microbiota, and organic acid content. Specifically, the probiotic intervention increased the population of Lactobacillus species, Clostridium coccoides group and C. leptum subgroup in the fecal microbial community. The number of blood bacteria was significantly reduced after the consumption of FMLCS and also hindered the bacterial translocation in T2D patients [44]. Similarly, the consumption of fermented milk containing L. acidophilus La-5 and B. animalis subsp. lactis BB-12 for 6 weeks showed significant changes in Hba1c, fructosamine levels, and reduced the inflammatory marker (TNF-α), resistin in T2D patients. The lipid profile of the probiotic-supplemented group was found to be improved (reduced the TC, and LDL content). The fecal organic acid assessment showed that fermented milk consumption increased the acetic acid content in fecal samples of the participants. The results suggested that probiotic consumption improved the glycemic control and inflammatory status of T2D patients [45].

Most of the studies evaluated the health-promoting effect of Lactobacillus, Bifidobacterium and Streptococcus species, especially L. acidophilus, B. breve, and S. thermophilus, respectively, in DM patients. The health-promoting potential of the intervention was found to be varied based on the type of the strain, concentration, and combinations of other probiotic strains, and also cointervention of prebiotics.

3. Probiotic Supplementation Showing No Positive Effect on Diabetic Condition

Though several studies showcased the potential of probiotic supplementation in the improvement of the health status of DM patients, some of the studies displayed negative results. The consumption of single strain probiotic (L. salivarius UCC118) for six weeks had no significant impact on the metabolic and glycemic status of GDM patients [46]. The supplementation of synbiotic formula (L. casei, L. acidophilus, L. rhamnosus, L. bulgaricus, B. breve, B. longum, S. thermophilus + FOS) showed no beneficial effect on the lipid profile (TC, LDL, HDL, TG) in prediabetic patients [47]. Mazloom et al. [48] also reported the nonsignificant changes in the glycemic status of T2D patients after the consumption of probiotic preparation (L. acidophilus, L. bulgaricus, L. casei, and B. bifidum) for six weeks.

4. Concluding Remarks

Several meta-analysis studies on results of clinical trials suggested that probiotic supplementation reduced the FPG, lipid profile, blood pressure, and other cardiovascular risk factors in T2D patients [49–53]. The probiotic supplements effectively controlled the glycemic and inflammatory status of GDM patients [30]. The possible mechanism of probiotics include increasing the fasting insulin concentration to reduce the FPG, increasing HDL and decreasing TC, TG, LDL to improve the lipid profile, decreasing the systolic and diastolic blood pressure to maintain the normal blood pressure. Thereby, probiotics reduces cardiovascular risk by controlling hypertension and dyslipidemia in individuals with T2DM. Probiotics controls the glycemic condition by reducing the insulin resistance and might decrease the production of
| Subjects     | Intervention                                                                 | Duration | Key observations                                                                                                      | Health claim                             | Reference(s) |
|--------------|------------------------------------------------------------------------------|----------|----------------------------------------------------------------------------------------------------------------------|------------------------------------------|--------------|
| T2D patients | Soy milk with *L. plantarum* A7                                                 | 8 weeks  | ↓ Urine albumin level                                                                                                 | Improved the kidney function             | [39]         |
|              |                                                                               |          | ↓ Serum creatinine, IL-18, sialic acid levels                                                                         |                                                          |              |
|              |                                                                               |          | Improved the GFR                                                                                                     |                                                          |              |
| DKD patients | Probiotic soy milk                                                            | 8 weeks  | ↑ Reduced GSH, GPx, glutathione reductase                                                                              | Improved the oxidative stress factors    | [40]         |
|              |                                                                               |          | ↓ Systemic inflammatory state, and inflammatory response                                                              |                                                          |              |
| T2D patients | Ecologic-Barrier                                                             | 26 weeks | ↓ Endotoxin levels                                                                                                   | Improved the systemic inflammatory status | [15]         |
|              |                                                                               |          | Altered the gut microbiota                                                                                           |                                                          |              |
| T2D patients | Ecologic-Barrier                                                             | 12 weeks | ↓ Waist-hip ratio                                                                                                    | Improved HOMA-IR score                   | [16]         |
|              |                                                                               |          | Improved HOMA-IR                                                                                                     |                                                          |              |
| T2D patients | Ecologic-Barrier                                                             | 6 months | ↑ GSH, GPx, glutathione reductase                                                                                   | Improved the oxidative stress factors    | [40]         |
|              |                                                                               |          | Altered the hs-CRP value                                                                                            | Improved the antioxidant status and mineral content | [18, 19]  |
| T2D patients | *L. acidophilus, L. casei, L. rhamninosus, L. bulgaricus, B. breve, B. longum, S. thermophilus* | 8 weeks  | Altered the hs-CRP value                                                                                            | Improved the antioxidant status and mineral content | [18, 19]  |
| T2D patients | *L. acidophilus, L. casei, L. rhamninosus, L. bulgaricus, B. breve, B. longum, S. thermophilus* and FOS | 6 weeks  | ↑ Serum GSH level                                                                                                   | Improved the glycemic status             | [20]         |
|              |                                                                               |          | ↑ Serum calcium level                                                                                                |                                                          |              |
| T2D patients | *L. acidophilus, L. casei, L. rhamninosus, L. bulgaricus, B. breve, B. longum, S. thermophilus and inulin* | 6 weeks  | ↑ Serum ALT                                                                                                          | Improved the metabolic status            | [21]         |
| T2D patients | Yogurt containing *L. acidophilus* La5 and *B. lactis* Bb12                   | 6 weeks  | ↓ FPG, HbA1c, MDA                                                                                                   | Improved the lipid profile and TAS       | [41, 42]     |
|              |                                                                               |          | ↑ SOD, GPx, and TAS                                                                                                 |                                                          |              |
| T2D patients | Yogurt containing *L. acidophilus* La5 and *B. lactis* Bb12                   | 4 weeks  | ↓ FPG, HbA1c, TG                                                                                                    | Improved the lipid profile and glycemic status | [43]         |
|              |                                                                               |          | ↓ LDL                                                                                                                |                                                          |              |
| T2D patients | *L. acidophilus, L. casei, L. lactis, B. bifidum, B. longum, and B. infantis* | 12 weeks | ↓ HbA1c, Fasting insulin level                                                                                       | Improved only HbA1c, fasting insulin level | [22]         |
Table 1: Continued.

| Subjects                  | Intervention                                                                 | Duration | Key observations                                                                 | Health claim                                                                 | Reference(s) |
|---------------------------|-----------------------------------------------------------------------------|----------|----------------------------------------------------------------------------------|-------------------------------------------------------------------------------|---------------|
| T2D patients              | *L. reuteri* ADR-1, and *L. reuteri* ADR-3                                 | 9 months | ↓ HbA1c, Cholesterol level; ↓ Blood pressure; ↑ Fecal *Lactobacillus* and *Bifidobacterium* load | Improved the fecal microbial composition                                      | [23]          |
| T2D patients              | *L. reuteri DSM 17938*                                                     | 12 weeks | ↑ Insulin sensitivity index; ↑ Serum deoxycholic acid                             | Improved insulin sensitivity                                                  | [24]          |
| T2D patients              | Symbiter                                                                    | 8 weeks  | ↓ HOMA-IR, HbA1c; ↓ Bacterial translocation                                       | Improved the insulin resistance                                              | [25]          |
| T2D patients              | *L. casei* strain Shirota fermented milk                                     | 16 weeks | ↑ *Clostridium cocoides* group; ↑ *C. leptum* subgroup, *Lactobacillus* species   | Reduced the bacterial translocation                                           | [44]          |
| T2D patients              | Fermented milk (*L. acidophilus* LA-5 and *B. animalis* subsp. lactis BB-12) | 6 weeks  | ↓ HbA1c, fructosamine levels; ↓ TNF-α and resistin                               | Improved the glycemic control                                                | [45]          |
| T2D patients              | *Lactobacillus* spp., *Bifidobacterium* spp., *S. thermophilus*, and FOS    | 9 weeks  | ↓ FPG, HbA1c, BMI; ↓ Microalbuminuria                                            | Improved the glucose level and DM-associated parameters                      | [26]          |
| T2D patients              | *L. acidophilus*, *B. bifidum* and FOS                                      | 30 days  | ↓ FPG, TC, TG, LDL; ↑ HDL                                                        | Improved the glycemic status                                                 | [27]          |
| T2D patients              | *L. acidophilus*, *L. casei*, *B. bifidum* and insulin                     | 12 weeks | ↓ FPG, insulin level, HOMA-β cell function; ↑ Insulin sensitivity index, HDL     | Improved the insulin metabolism                                              | [28]          |
| T2D patients with CHD     | *L. salivarius* UBL5, *L. casei* UBLC42, *L. acidophilus* UBLA34, *B. breve* UBB01, *Bacillus coagulans* Unique-IS2, and FOS | 12 weeks | ↓ FPG, postprandial blood sugar, insulin level, HOMA-1R                          | Improved the HRQL                                                             | [29]          |
| GDM patients              | *L. acidophilus* LA-5, *Bifidobacterium* BB-12, *S. thermophilus* STY-31, and *L. delbrueckii bulgaricus* LBY-27 | 8 weeks  | ↓ FPG; ↓ Weight gain; ↓ FPG                                                       | Influenced the weight gain and glucose metabolism                             | [31]          |
| GDM patients              | *L. acidophilus* LA-5, *Bifidobacterium* BB-12, *S. thermophilus* STY-31, and *L. delbrueckii bulgaricus* LBY-27 | 8 weeks  | ↓ Insulin resistance index; ↓ Insulin sensitivity index; ↓ TNF-α                 | Improved inflammation and antioxidant status                                 | [32]          |
| GDM patients              | VSL#3                                                                       | 8 weeks  | ↓ hs-CRP value; ↓ IL-6, MDA, uric acid; ↓ Glutathione reductase, SOD, TAS No change in FPG, HbA1c values, and insulin level | Improved the inflammatory markers                                             | [33]          |
Table 1: Continued.

| Subjects           | Intervention                                                                 | Duration | Key observations                                                                                                           | Health claim          | Reference(s) |
|--------------------|------------------------------------------------------------------------------|----------|--------------------------------------------------------------------------------------------------------------------------|-----------------------|--------------|
| GDM patients       | L. acidophilus, *L. casei* and *B. bifidum*                                   | 6 weeks  | ↓ FPG, insulin level, HOMA-IR, HOMA-β-cell function  ↓ TG, VLDL  ↑ Insulin sensitivity                                    | Glycemic control      | [34]         |
| GDM patients       | Infloran®                                                                    | 4 weeks  | ↓ FPG, fasting insulin level, HOMA-IR                                                                                  | Glycemic control      | [35]         |
| GDM patients       | *L. rhamnosus* HN001                                                         | —        | ↓ Relative rate of GDM                                                                                                    | Reduced the GDM prevalence | [36]         |
| Pre-diabetic patients | Probiotics (*L. acidophilus, B. lactis, B. bifidum, and B. longum*); Synbiotic (probiotics + inulin) | 24 weeks | ↓ FPG, fasting insulin level, HOMA-IR, HbA1c  ↑ QUICKI score  ↓ Hyperglycemia, hypertension  ↓ HDL-cholesterol level  ↓ Metabolic syndrome associated parameters | Glycemic improvement   | [37]         |
| Pre-diabetic patients | Probiotics (*L. acidophilus, B. lactis, B. bifidum, and B. longum*); Synbiotic (probiotics + inulin) | 24 weeks |                                                                                                                         | Improved the metabolic syndrome | [38]         |

T2D: Type 2 diabetes; DKD: Diabetic kidney disease; IL-18: Interleukin-18; GFR: Glomerular filtration rate; HOMA: Homeostasis model of assessment; HOMA-IR: Homeostasis model of assessment-insulin resistance; VLDL: Very low-density lipoprotein LDL: Low-density lipoprotein; HDL: High-density lipoprotein; hs-CRP: High-sensitivity C-reactive protein; GSH: Glutathione; TG: Triglycerides; AET: Alanine aminotransferase; GDM: Gestational diabetes mellitus; DM: Diabetes mellitus; HbA1c: Hemoglobin A1c; BMI: Body mass index; TC: Total cholesterol; SOD: Superoxide dismutase; GPx: Glutathione peroxidase; TAS: Total antioxidant status; MDA: Malondialdehyde; TNF-α: Tumor necrosis factor-α; QUICKI: Quantitative insulin sensitivity check index; CHD: Coronary heart disease; HRQL: Health-related quality of life; FOS: Fructooligosaccharide.
inflammatory markers in individuals with T2DM. Probiotic formulations showed promising results in most of the studies, except in some cases [46–48].

In general, clinical studies were conducted in a prescribed procedure. Though most of them are randomized, blinded, placebo-controlled studies, some of the limitations are there in any one or more of the following: sample size, preparation of supplements, monitoring of intervention, sampling, inconsistency in measurements, bias in the questionnaire, and rarely, study protocol. In addition, patient's physiology, combination and types of probiotics used, and experimental duration and follow-up period also influence the outcome of clinical trials. Thus, further well-designed studies are needed to understand the link between the role of the microbiome, the interaction of probiotics with host microbiota, and glycemmic control.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Bhagavathi Sundaram Sivamaruthi contributed to the conception and design, acquisition, manuscript preparation, and critical revision of the manuscript. Periyanaina Kesika and Chaiyavat Chaiyasut were involved in the review and finalization of the manuscript. All the authors agree with the content of the manuscript. Periyanaina Kesika and Bhagavathi Sundaram Sivamaruthi are contributed equally.

Acknowledgments

Bhagavathi Sundaram Sivamaruthi wishes to acknowledge the CMU Post-Doctoral Fellowship, Chiang Mai University, Chiang Mai, Thailand. The authors gratefully acknowledge the Faculty of Pharmacy, and Chiang Mai University, Chiang Mai, Thailand.

References

[1] India State-Level Disease Burden Initiative Diabetes Collaborators, “The increasing burden of diabetes and variations among the states of India: the Global Burden of Disease Study 1990–2016,” Lancet Global Health, vol. 6, no. 12, pp. e1352–e1362, 2018.
[2] W. R. Rowley, C. Bezold, Y. Arikann, E. Byrne, and S. Krohe, “Diabetes 2030: insights from yesterday, today, and future trends,” Population Health Management, vol. 20, no. 1, pp. 6–12, 2017.
[3] C. Bommer, V. Sagalova, E. Heesemann et al., “Global economic burden of diabetes in adults: projections from 2015 to 2030,” Diabetes Care, vol. 41, no. 5, pp. 963–970, 2018.
[4] A. Cannon, Y. Handelsman, M. Heile, and M. Shannon, “Burden of illness in type 2 diabetes mellitus,” Journal of Managed Care & Specialty Pharmacy, vol. 24, no. 9-aSuppl, pp. S5–S13, 2018.
[5] M. Peyrot, R. R. Rubin, T. Lauritzen, F. J. Snoek, D. R. Matthews, and S. E. Skovlund, “Psychosocial problems and barriers to improved diabetes management: results of the cross-national diabetes attitudes, wishes and needs (DAWN) study,” Diabetic Medicine, vol. 22, no. 10, pp. 1379–1385, 2005.
[6] N. G. Vallianou, T. Stratigou, and S. Tsagarakis, “Microbiome and diabetes: where are we now?,” Diabetes Research and Clinical Practice, vol. 146, pp. 111–118, 2018.
[7] D. Festi, R. Schiumerini, L. H. Eusebi, G. Marasco, M. Taddia, and A. Colecchia, “Gut microbiota and metabolic syndrome,” World Journal of Gastroenterology, vol. 20, no. 43, pp. 16079–16094, 2014.
[8] C. Hill, F. Guarnier, G. Reid et al., “Expert consensus document: the international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic,” Nature Reviews Gastroenterology & Hepatology, vol. 11, no. 8, pp. 506–514, 2014.
[9] B. S. Sivamaruthi, “A comprehensive review on clinical outcome of probiotic and synbiotic therapy for inflammatory bowel diseases,” Asian Pacific Journal of Tropical Biomedicine, vol. 8, no. 3, pp. 179–186, 2018.
[10] B. S. Sivamaruthi, P. Kesika, and C. Chaiyasut, “Probiotic based therapy for atopic dermatitis: outcomes of clinical studies-A mini review,” Asian Pacific Journal of Tropical Biomedicine, vol. 8, no. 6, pp. 328–332, 2018.
[11] B. S. Sivamaruthi, P. Kesika, and C. Chaiyasut, “Influence of probiotic supplementation on climacteric symptoms in menopausal women - a mini review,” International Journal of Applied Pharmaceutics, vol. 10, no. 6, pp. 43–46, 2018.
[12] B.S. Sivamaruthi, P. Kesika, and C. Chaiyasut, “A review on antiaging properties of probiotics,” International Journal of Applied Pharmaceutics, vol. 10, no. 5, pp. 23–27, 2018.
[13] B.S.Sivamaruthi, M.I. Prasanth, P. Kesika, and C. Chaiyasut, “Role of probiotics in human mental health and diseases-a mini review,” Tropical Journal of Pharmaceutical Research, 2019, (In press).
[14] J. de la Cuesta-Zuluaga, N. T. Mueller, V. Vanessa Corrales-Agudeo et al., “Metformin is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short chain fatty acid-producing microbiota in the gut,” Diabetes Care, vol. 40, no. 1, pp. 54–62, 2017.
[15] M. S. Alokail, S. Sabico, Y. Al-Saleh et al., “Effects of probiotics in patients with diabetes mellitus type 2: study protocol for a randomized, double-blind, placebo-controlled trial,” Trials, vol. 14, no. 1, p. 195, 2013.
[16] S. Sabico, A. Al-Mashharawi, N. M. Al-Daghri et al., “Effects of a multistrain probiotic supplement for 12 weeks in circulating endotoxin levels and cardiometabolic profiles of medication naïve T2DM patients: a randomized clinical trial,” Journal of Translational Medicine, vol. 15, no. 1, p. 249, 2017.
[17] S. Sabico, A. Al-Mashharawi, N. M. Al-Daghri et al., “Effects of a 6-month multistrain probiotics supplementation in endotoxemic, inflammatory and cardiometabolic status of T2DM patients: a randomized, double-blind, placebo-controlled trial,” Clinical Nutrition, vol. 38, no. 4, pp. 1561–1569, 2019.
[18] Z. Asemi, Z. Zare, H. Shakeri, S. S. Sabih, and A. Esmaillzadeh, “Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes,” Annals of Nutrition and Metabolism, vol. 63, no. 1–2, pp. 1–9, 2013.
[19] Z. Asemi, S. Bahmani, H. Shakeri, A. Jamal, and A. Faraji, “Effect of multispecies probiotic supplements on serum minerals, liver
enzymes and blood pressure in patients with type 2 diabetes,” *International Journal of Diabetes in Developing Countries*, vol. 35, no. 2, pp. 90–95, 2015.

[20] E. Razmpooosh, A. Javadi, H. S. Ejtahed, P. Mirmiran, M. Javadi, and A. Yousefnejad, “The effect of probiotic supplementation on glycemic control and lipid profile in patients with type 2 diabetes: a randomized placebo controlled trial,” *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, vol. 13, no. 1, pp. 175–182, 2019.

[21] Z. Asemi, A. Khorrami-Rad, S. A. Alizadeh, H. Shakeri, and A. Esmailzadeh, “Effects of symbiotic food consumption on metabolic status of diabetic patients: a double-blind randomized cross-over controlled clinical trial,” *Clinical Nutrition*, vol. 33, no. 2, pp. 198–203, 2014.

[22] S. Firouzi, H. A. Majid, A. Ismail, N. A. Kamaruddin, and M. Y. Barakatun-Nisak, “Effect of multistrain probiotics (multistrain microbial cell preparation) on glycemic control and other diabetes-related outcomes in people with type 2 diabetes: a randomized controlled trial,” *European Journal of Nutrition*, vol. 56, no. 4, pp. 1535–1550, 2017.

[23] M. C. Hsieh, W. H. Tsai, Y. P. Jheng et al., “The beneficial effects of *Lactobacillus reuteri* ADR-1 or ADR-3 consumption on type 2 diabetes mellitus: a randomized, double-blinded, placebo-controlled trial,” *Scientific Reports*, vol. 8, no. 1, p. 16791, 2018.

[24] R. Mobini, V. Tremaroli, M. Stahlman et al., “Metabolic effects of *Lactobacillus reuteri* DSM 17938 in people with type 2 diabetes: a randomized controlled trial,” *Diabetes, Obesity and Metabolism*, vol. 19, no. 4, pp. 579–589, 2017.

[25] N. Kobyliał, T. Falalveyeva, G. Mykhalychshyn, D. Kyriienko, and I. Komissarenko, “Effect of alive probiotic on insulin resistance in type 2 diabetes patients: randomized clinical trial,” *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, vol. 12, no. 5, pp. 617–624, 2018.

[26] Z. S. Ebrahimi, E. Nasli-Esfahani, A. Nadjarzade, and H. Mozaffari-Khosravi, “Effect of symbiotic supplementation on glycemic control, lipid profiles and microalbuminuria in patients with non-obese type 2 diabetes: a randomized, double-blind, clinical trial,” *Journal of Diabetes & Metabolic Disorders*, vol. 16, no. 1, p. 23, 2017.

[27] C. Moroti, L. F. Souza Magri, M. de Rezende Costa, D. C. Cavallini, and K. Sivieri, “Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus,” *Lipids in Health and Disease*, vol. 11, no. 1, p. 29, 2012.

[28] M. Tajabadi-Ebrahimi, N. Sharifi, A. Farrokhi, and A. Yousefnejad et al., “A randomized controlled clinical trial investigating the effect of symbiotic administration on markers of insulin metabolism and lipid profiles in overweight type 2 diabetic patients with coronary heart disease,” *Experimental and Clinical Endocrinology & Diabetes*, vol. 125, no. 1, pp. 21–27, 2016.

[29] R. Venkataraman, P. Jose, and J. Jose, “Impact of probiotics on health-related quality of life in type II diabetes mellitus: a randomized single-blind, placebo-controlled study,” *Journal of Natural Science, Biology and Medicine*, vol. 10, no. 1, pp. 2–7, 2019.

[30] S. Dallonora, Y. Medeiros de Souza, R. G. Deon et al., “Do probiotics effectively ameliorate glycemic control during gestational diabetes? A systematic review,” *Archives of Gynecology and Obstetrics*, vol. 298, no. 3, pp. 477–485, 2018.

[31] N. Dolatkhah, M. Hajifaraji, F. Abbasalizadeh, N. Aghamohammadmzadeh, Y. Mehrabi, and M. M. Abbasi, “Is there a value for probiotic supplements in gestational diabetes mellitus? A randomized clinical trial,” *Journal of Health, Population and Nutrition*, vol. 33, no. 1, p. 25, 2015.

[32] M. Hajifaraji, F. Jahanjou, F. Abbasalizadeh, N. Aghamohammadmzadeh, M. M. Abbasi, and N. Dolatkhah, “Effect of probiotic supplements in women with gestational diabetes mellitus on inflammation and oxidative stress biomarkers: a randomized clinical trial,” *Asia Pacific Journal of Clinical Nutrition*, vol. 27, no. 3, pp. 581–591, 2018.

[33] S. Jafarnejad, S. Sarem, F. Jafarnejad, and A. Arab, “Effects of a multispecies probiotic mixture on glycemic control and inflammatory status in women with gestational diabetes: a randomized controlled clinical trial,” *Journal of Nutrition and Metabolism*, vol. 2016, pp. 1–8, 2016.

[34] M. Karamali, F. Dadkhah, M. Sadrekhanlou et al., “Effects of probiotic supplementation on glycemic control and lipid profiles in gestational diabetes: a randomized, double-blind, placebo-controlled trial,” *Diabetes, Obesity and Metabolism*, vol. 42, no. 4, pp. 234–241, 2016.

[35] A. Kijmanawan, P. Panburana, S. Reutrakul, and C. Tangshewinsirikul, “Effects of probiotic supplements on insulin resistance in gestational diabetes mellitus: a double-blind randomized controlled trial,” *Journal of Diabetes Investigation*, vol. 10, no. 1, pp. 163–170, 2019.

[36] K. L. Wickens, C. A. Barthow, R. Murphy et al., “Early pregnancy probiotic supplementation with *Lactobacillus rhamnosus* HH001 may reduce the prevalence of gestational diabetes mellitus: a randomized controlled trial,” *British Journal of Nutrition*, vol. 117, no. 6, pp. 804–813, 2017.

[37] N. Kassaian, A. Feizi, A. Aminorroaya, P. Jafari, M. T. Ebrahimii, and M. Amini, “The effects of probiotics and symbiotic supplementation on glucose and insulin metabolism in adults with prediabetes: a double-blind randomized clinical trial,” *Acta Diabetologica*, vol. 55, no. 10, pp. 1019–1028, 2018.

[38] N. Kassaian, A. Feizi, A. Aminorroaya, and M. Amini, “Probiotic and symbiotic supplementation could improve metabolic syndrome in prediabetic adults: a randomized controlled trial,” *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, 2018.

[39] B. Abbasi, R. Ghasvand, and M. Mirlohi, “Kidney Function improvement by soy milk containing *Lactobacillus plantarum* A7 in type 2 diabetic patients with nephropathy: a double-blind randomized controlled trial,” *Iranian Journal Kidney Diseases*, vol. 11, no. 1, pp. 36–43, 2017.

[40] M. Miraghasani, N. Zaghian, M. Mirlohi, A. Feizi, and R. Ghasvand, “The impact of probiotic soy milk consumption on oxidative stress among type 2 diabetic kidney disease patients: a randomized controlled clinical trial,” *Journal of Renal Nutrition*, vol. 27, no. 5, pp. 317–324, 2017.

[41] H. S. Ejtahed, J. Mohtadi-Nia, A. Homayouni-Rad et al., “Effect of probiotic yogurt containing *Lactobacillus acidophilus* and *Bifidobacterium lactis* on lipid profile in individuals with type 2 diabetes mellitus,” *Journal of Dairy Sciences*, vol. 94, no. 7, pp. 3288–3294, 2011.

[42] H. S. Ejtahed, J. Mohtadi-Nia, A. Homayouni-Rad, M. Niafar, M. Aghaee-Jafarabadi, and V. Mofid, “Probiotic yogurt improves antioxidant status in type 2 diabetic patients,” *Nutrition*, vol. 28, no. 5, pp. 539–543, 2012.

[43] M. Rezaei, A. Sanagoo, L. Jouybari, N. Behnampoor, and A. Kavosi, “The effect of probiotic yogurt on blood glucose and cardiovascular biomarkers in patients with type II diabetes: a randomized controlled trial,” *Evidence Based Care Journal*, vol. 6, no. 4, pp. 26–35, 2017.
[44] J. Sato, A. Kanazawa, K. Azuma et al., “Probiotic reduces bacterial translocation in type 2 diabetes mellitus: A randomised controlled study,” *Scientific Reports*, vol. 7, no. 1, Article ID 12115, 2017.

[45] L. B. Tonucci, K. M. Olbrich Dos Santos, L. Licursi de Oliveira, S. M. Rocha Ribeiro, and H. S. Duarte Martino, “Clinical application of probiotics in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study,” *Clinical Nutrition*, vol. 36, no. 1, pp. 85–92, 2017.

[46] K. L. Lindsay, L. Brennan, M. A. Kennelly et al., “Impact of probiotics in women with gestational diabetes mellitus on metabolic health: a randomized controlled trial,” *American Journal of Obstetrics and Gynecology*, vol. 212, no. 4, pp. 496e1–496e11, 2015.

[47] S. Mahboobi, B. Iraj, Z. Maghsoudi et al., “The effects of probiotic supplementation on markers of blood lipids, and blood pressure in patients with prediabetes: a randomized clinical trial,” *International Journal of Preventive Medicine*, vol. 5, no. 10, pp. 1239–12346, 2014.

[48] Z. Mazloom, A. Yousefinejad, and M. H. Dabbaghanesh, “Effect of probiotics on lipid profile, glycemic control, insulin action, oxidative stress, and inflammatory markers in patients with type 2 diabetes: a clinical trial,” *Iranian Journal of Medical Sciences*, vol. 38, no. 1, pp. 38–43, 2013.

[49] M. A. Kasińska and J. Drzewoski, “Effectiveness of probiotics in type 2 diabetes: a meta-analysis,” *Polish Archives of Internal Medicine*, vol. 125, no. 11, pp. 803–813, 2015.

[50] V. Akbari and F. Hendijani, “Effects of probiotic supplementation in patients with type 2 diabetes: systematic review and meta-analysis,” *Nutrition Review*, vol. 74, no. 12, pp. 774–784, 2016.

[51] J. He, F. Zhang, and Y. Han, “Effect of probiotics on lipid profiles and blood pressure in patients with type 2 diabetes: a meta-analysis of RCTs,” *Medicine*, vol. 96, no. 51, p. e9166, 2017.

[52] F. Hendijani and V. Akbari, “Probiotic supplementation for management of cardiovascular risk factors in adults with type II diabetes: a systematic review and meta-analysis,” *Clinical Nutrition*, vol. 37, no. 2, pp. 532–541, 2018.

[53] E. Nikbakht, S. Khalesi, I. Singh, L. T. Williams, N. P. West, and N. Colson, “Effect of probiotics and synbiotics on blood glucose: a systematic review and meta-analysis of controlled trials,” *European Journal of Nutrition*, vol. 57, no. 1, pp. 95–106, 2018.